{
    "body": "What do mepolizumab and reslizumab have in common?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22541618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21824072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26285457", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25671117", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22092535", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23742015", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24275927", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20565230", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19037962"
    ], 
    "ideal_answer": [
        "Mepolizumab and reslizumab are monoclonal antibodies that target and neutralize interleukin 5. They have been shown to reduce eosinophil counts and they are used for the treatment of refractory asthma (associated with eosiniphilia) and other eosinophilic diseases."
    ], 
    "exact_answer": [
        [
            "monoclonal antibodies"
        ], 
        [
            "treatment for refractory asthma"
        ], 
        [
            "treatment for eosinophilic disease"
        ], 
        [
            "neutralize interleukin 5"
        ], 
        [
            "reduce eosinophil counts"
        ]
    ], 
    "concepts": [
        "http://www.biosemantics.org/jochem#4002251", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015848"
    ], 
    "type": "list", 
    "id": "56cf2be73975bb303a000005", 
    "snippets": [
        {
            "offsetInBeginSection": 992, 
            "offsetInEndSection": 1224, 
            "text": "The most promising agents are targeted against cytokines of Th2 pattern and related receptors, such as IL-2 (daclizumab) and IL-13 (lebrikizumab) or IL-5 in patients with hypereosinophilia (mepolizumab, reslizumab and benralizumab).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25671117", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 105, 
            "text": "Patients with severe asthma or COPD have often a suboptimal symptom control due to inadequate treatment. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25671117", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 712, 
            "offsetInEndSection": 1214, 
            "text": "For example, patients with the hypereosinophilic syndrome have received mepolizumab, an anti-IL-5 monoclonal antibody, for as long as 6 years and have not developed any characteristic set of adverse events. Safety data for reslizumab, another anti-IL-5 monoclonal antibody, and benralizumab, a monoclonal antibody to the IL-5 receptor \u03b1-chain, are comparatively limited, especially for benralizumab, although reports of administration of these antibodies to humans suggest that they are well tolerated.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23742015", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 513, 
            "offsetInEndSection": 751, 
            "text": "IL-5 antagonist therapies in current development include two monoclonal anti-IL-5 antibodies (mepolizumab, reslizumab), a monoclonal antibody directed at the IL-5 receptor (benralizumab), and anti-sense oligonucleotide therapy (TPI ASM8).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22541618", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1123, 
            "offsetInEndSection": 1634, 
            "text": "In patients with severe, refractory asthma associated with eosinophilia, however, clinical trials have demonstrated significant reductions in asthma exacerbations. Clinical studies in other disorders, particularly eosinophilic esophagitis and hypereosinophilic syndrome, have also shown significant improvements in blood and/or tissue eosinophilia and variable alterations in clinical disease activity. Strategies aimed at the inhibition of IL-5 may hold great promise in the treatment of eosinophilic diseases.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22541618", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 959, 
            "offsetInEndSection": 1145, 
            "text": "Two monoclonal antibodies have been designed to neutralize IL-5 (mepolizumab and reslizumab). Both antibodies have demonstrated the ability to reduce blood and tissue eosinophil counts. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22092535", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1048, 
            "offsetInEndSection": 1141, 
            "text": "Two monoclonal antibodies have been designed to neutralize IL-5 (mepolizumab and reslizumab).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22092535", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 699, 
            "offsetInEndSection": 817, 
            "text": "To date, two humanized monoclonal antibodies, mepolizumab and reslizumab, have been developed that bind to human IL-5.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21824072", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 275, 
            "offsetInEndSection": 439, 
            "text": "Monoclonal antibodies directed towards interleukin-5, such as mepolizumab or reslizumab, were shown to be very effective at reducing blood and airways eosinophilia.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26285457", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 748, 
            "offsetInEndSection": 986, 
            "text": "IL-5 antagonist therapies in current development include two monoclonal anti-IL-5 antibodies (mepolizumab, reslizumab), a monoclonal antibody directed at the IL-5 receptor (benralizumab), and anti-sense oligonucleotide therapy (TPI ASM8).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22541618", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1217, 
            "offsetInEndSection": 1449, 
            "text": "The most promising agents are targeted against cytokines of Th2 pattern and related receptors, such as IL-2 (daclizumab) and IL-13 (lebrikizumab) or IL-5 in patients with hypereosinophilia (mepolizumab, reslizumab and benralizumab).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25671117", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 277, 
            "text": "Asthma is a chronic inflammatory disease that often features eosinophilia, especially in its most severe forms. Monoclonal antibodies directed towards interleukin-5, such as mepolizumab or reslizumab, were shown to be very effective at reducing blood and airways eosinophilia. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26285457", 
            "endSection": "abstract"
        }
    ]
}